Living Through the Fentanyl Era

How a single synthetic opioid rewired the American drug supply — and what comes next.

ByThe Rize NewsroomApril 25, 20261 min readOpioids

It is impossible to write about American drug use in 2026 without writing about fentanyl. By volume, illicit fentanyl is now the dominant opioid in nearly every U.S. drug market — replacing heroin in some regions entirely and adulterating cocaine, methamphetamine, and counterfeit pills across all of them.

The substance itself is not new. Fentanyl was first synthesized in 1959 and has been a cornerstone of clinical anesthesia for decades. What is new is its presence in the unregulated supply.

How we got here

The 2010s pivot from prescription-led to synthetic-led overdose mortality is well-documented. What is less appreciated is how completely fentanyl has reorganized every layer of the drug supply chain — from precursor sourcing in China and India, to clandestine pressing in Mexico, to retail-level distribution in U.S. cities.

What this means for people who use opioids

Fentanyl’s potency — 50 to 100 times that of morphine — leaves no margin for error. A single dose variation that would be inconsequential in heroin can be fatal in a fentanyl-adulterated counterfeit pill.

This is why harm reduction is no longer optional. Naloxone, fentanyl test strips, and never-use-alone protocols are not lifestyle preferences — they are the basic infrastructure of survival in the post-fentanyl era.

What’s coming

Xylazine. Medetomidine. Nitazenes. The post-fentanyl supply will keep evolving. Drug-checking services that can detect novel adulterants in real time are the most consequential public-health intervention of the next five years.

For more on harm reduction strategies, see our running coverage.

Sources Cited

01.A
National Drug Threat Assessment 2024DEA
02.A
Medications for Substance Use DisordersSAMHSA

Filed Under

trendsharm-reductionsocial-culturalOverdoseFentanyl Test StripsNaloxoneInvestigative Journalism

More from this section

Harm Reduction

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.

Harm Reduction

Responding to the Emerging Threat of Xylazine

On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.

Harm Reduction

The Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook

Medetomidine, a veterinary sedative 200 times more potent than xylazine, has displaced xylazine in Philadelphia's fentanyl supply and is confirmed in nine states. It produces sedation that naloxone cannot reverse, withdrawal that requires ICU-level care in 91% of hospitalized patients, and clinical presentations that emergency departments are consistently misidentifying.